Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors

Seyoung Koo; Kondapa Naidu Bobba; Mi Young Cho; Hye Sun Park; Miae Won; Nithya Velusamy; Kwan Soo Hong; Sankarprasad Bhuniya; Jong Seung Kim

doi:10.1021/acsabm.9b00722

Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors

Seyoung Koo, Kondapa Naidu Bobba, Mi Young Cho, Hye Sun Park, Miae Won, Nithya Velusamy, Kwan Soo Hong, Sankarprasad Bhuniya, Jong Seung Kim

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

A theranostic, small-molecule-based prodrug, designed to be activated programmatically against hypoxic tumors, was successfully developed. The prodrug was stimulated to release the active chemotherapeutic drug in concurrent with a rhodol fluorophore in artificial hypoxia mimic conditions or an in vitro hypoxic environment. The extent of prodrug activation was monitored under the hypoxia condition by monitoring a fluorescence signal at 543 nm. The excellent therapeutic response and selective fluorescence labeling of biotin receptor overexpressed cancer cells ensured that the prodrug could be an effective strategy for the therapy of chronic hypoxic tumors.

Original language	English
Pages (from-to)	4648-4655
Number of pages	8
Journal	ACS Applied Bio Materials
Volume	2
Issue number	10
DOIs	https://doi.org/10.1021/acsabm.9b00722
Publication status	Published - 2019 Oct 21

Bibliographical note

Funding Information:
This work is supported by a National Research Council of Science and Technology (NST) grant (CAP-18-02-KRIBB, K.S.H.) from the Korea government (MSIP), KBSI grant (T39631, K.S.H.), Science and Engineering Research Board, India (ECR/2015/00035, S.B.), Brain Pool fellowship program, National Research Foundation of Korea (2018H1D3A2002203, S.B.), Council of Scientific & Industrial Research, India (02(0386)19/EMR II, S.B.), and National Research Foundation of Korea (CRI 2018R1A3B1052702, J.S.K.).

Publisher Copyright:
© 2019 American Chemical Society.

Keywords

antitumor
drug targeting
hypoxia
prodrug
theranostic

ASJC Scopus subject areas

Biomaterials
General Chemistry
Biomedical Engineering
Biochemistry, medical

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/acsabm.9b00722

Cite this

@article{b6454637382f4c62bb34e306acdcd020,

title = "Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors",

abstract = "A theranostic, small-molecule-based prodrug, designed to be activated programmatically against hypoxic tumors, was successfully developed. The prodrug was stimulated to release the active chemotherapeutic drug in concurrent with a rhodol fluorophore in artificial hypoxia mimic conditions or an in vitro hypoxic environment. The extent of prodrug activation was monitored under the hypoxia condition by monitoring a fluorescence signal at 543 nm. The excellent therapeutic response and selective fluorescence labeling of biotin receptor overexpressed cancer cells ensured that the prodrug could be an effective strategy for the therapy of chronic hypoxic tumors.",

keywords = "antitumor, drug targeting, hypoxia, prodrug, theranostic",

author = "Seyoung Koo and Bobba, {Kondapa Naidu} and Cho, {Mi Young} and Park, {Hye Sun} and Miae Won and Nithya Velusamy and Hong, {Kwan Soo} and Sankarprasad Bhuniya and Kim, {Jong Seung}",

note = "Funding Information: This work is supported by a National Research Council of Science and Technology (NST) grant (CAP-18-02-KRIBB, K.S.H.) from the Korea government (MSIP), KBSI grant (T39631, K.S.H.), Science and Engineering Research Board, India (ECR/2015/00035, S.B.), Brain Pool fellowship program, National Research Foundation of Korea (2018H1D3A2002203, S.B.), Council of Scientific & Industrial Research, India (02(0386)19/EMR II, S.B.), and National Research Foundation of Korea (CRI 2018R1A3B1052702, J.S.K.). Publisher Copyright: {\textcopyright} 2019 American Chemical Society.",

year = "2019",

month = oct,

day = "21",

doi = "10.1021/acsabm.9b00722",

language = "English",

volume = "2",

pages = "4648--4655",

journal = "ACS Applied Bio Materials",

issn = "2576-6422",

publisher = "American Chemical Society",

number = "10",

}

TY - JOUR

T1 - Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors

AU - Koo, Seyoung

AU - Bobba, Kondapa Naidu

AU - Cho, Mi Young

AU - Park, Hye Sun

AU - Won, Miae

AU - Velusamy, Nithya

AU - Hong, Kwan Soo

AU - Bhuniya, Sankarprasad

AU - Kim, Jong Seung

N1 - Funding Information: This work is supported by a National Research Council of Science and Technology (NST) grant (CAP-18-02-KRIBB, K.S.H.) from the Korea government (MSIP), KBSI grant (T39631, K.S.H.), Science and Engineering Research Board, India (ECR/2015/00035, S.B.), Brain Pool fellowship program, National Research Foundation of Korea (2018H1D3A2002203, S.B.), Council of Scientific & Industrial Research, India (02(0386)19/EMR II, S.B.), and National Research Foundation of Korea (CRI 2018R1A3B1052702, J.S.K.). Publisher Copyright: © 2019 American Chemical Society.

PY - 2019/10/21

Y1 - 2019/10/21

N2 - A theranostic, small-molecule-based prodrug, designed to be activated programmatically against hypoxic tumors, was successfully developed. The prodrug was stimulated to release the active chemotherapeutic drug in concurrent with a rhodol fluorophore in artificial hypoxia mimic conditions or an in vitro hypoxic environment. The extent of prodrug activation was monitored under the hypoxia condition by monitoring a fluorescence signal at 543 nm. The excellent therapeutic response and selective fluorescence labeling of biotin receptor overexpressed cancer cells ensured that the prodrug could be an effective strategy for the therapy of chronic hypoxic tumors.

AB - A theranostic, small-molecule-based prodrug, designed to be activated programmatically against hypoxic tumors, was successfully developed. The prodrug was stimulated to release the active chemotherapeutic drug in concurrent with a rhodol fluorophore in artificial hypoxia mimic conditions or an in vitro hypoxic environment. The extent of prodrug activation was monitored under the hypoxia condition by monitoring a fluorescence signal at 543 nm. The excellent therapeutic response and selective fluorescence labeling of biotin receptor overexpressed cancer cells ensured that the prodrug could be an effective strategy for the therapy of chronic hypoxic tumors.

KW - antitumor

KW - drug targeting

KW - hypoxia

KW - prodrug

KW - theranostic

UR - http://www.scopus.com/inward/record.url?scp=85073170478&partnerID=8YFLogxK

U2 - 10.1021/acsabm.9b00722

DO - 10.1021/acsabm.9b00722

M3 - Article

C2 - 35021423

AN - SCOPUS:85073170478

SN - 2576-6422

VL - 2

SP - 4648

EP - 4655

JO - ACS Applied Bio Materials

JF - ACS Applied Bio Materials

IS - 10

ER -

Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this